MS021

MS021 is a preclinical-stage monoclonal antibody developed by Medimscience, designed to target MT021, a proprietary macrophage-related protein. The therapeutic candidate is being developed for the treatment of solid tumors and Graft-versus-Host Disease (GVHD). By interacting with MT021 on macrophages, MS021 aims to modulate immune responses within the tumor microenvironment or systemic inflammatory conditions. As of current reports, the asset remains in the preclinical phase of development, with its exact mechanism of action involving the regulation of macrophage activity to achieve anti-tumor or anti-inflammatory effects.